News & Sentiment
Restaurant Brands International Inc. Announces Renewal of Normal Course Issuer Bid
MIAMI, Sept. 11, 2026 /CNW/ -- Restaurant Brands International Inc. (TSX: QSR) (NYSE: QSR) ("RBI") announced today that it has filed, and the Toronto Stock Exchange (the "TSX") has accepted, notice of RBI's intention to renew its normal course issuer bid (the "NCIB") for its common shares....
All
Basic Materials
Communication Services
Consumer Cyclical
Consumer Defensive
Energy
Financial Services
Healthcare
Industrials
Real Estate
Technology
Utilities
Macro
All Sentiment
Bullish
Neutral
Bearish
1,167 articles
📰
Why Teladoc (TDOC) Outpaced the Stock Market Today
Teladoc (TDOC) reached $6.16 at the closing of the latest trading day, reflecting a +1.15% change compared to its last close.
📰
Novavax (NVAX) Laps the Stock Market: Here's Why
In the most recent trading session, Novavax (NVAX) closed at $9.42, indicating a +1.29% shift from the previous trading day.
CAH Gains More Than 29% in 4 Months: Will the Uptrend Continue?
Cardinal Health's 29% rally reflects stronger specialty growth, MSO expansion and higher-margin assets, but cost pressures could test the uptrend.
BTSG Gains More Than 54% YTD: Should You Buy, Hold or Sell?
BrightSpring Health Services has surged 54% YTD on specialty pharmacy, infusion and EBITDA growth, but premium valuation and policy headwinds remain.
BTSG Gains More Than 54% YTD: Should You Buy, Hold or Sell?
BrightSpring Health Services has surged 54% YTD on specialty pharmacy, infusion and EBITDA growth, but premium valuation and policy headwinds remain.
BTSG Gains More Than 54% YTD: Should You Buy, Hold or Sell?
BrightSpring Health Services has surged 54% YTD on specialty pharmacy, infusion and EBITDA growth, but premium valuation and policy headwinds remain.
CAH Gains More Than 29% in 4 Months: Will the Uptrend Continue?
Cardinal Health's 29% rally reflects stronger specialty growth, MSO expansion and higher-margin assets, but cost pressures could test the uptrend.
CAH Gains More Than 29% in 4 Months: Will the Uptrend Continue?
Cardinal Health's 29% rally reflects stronger specialty growth, MSO expansion and higher-margin assets, but cost pressures could test the uptrend.
📰
1 Thing I Wish I'd Known About the Stock Market When I First Started Investing
What is the most expensive habit a new investor can pick up? Taking quick profits on a company worth owning for decades.
📰
Could This New Opportunity Be Worth Billions for Novo Nordisk?
The worst may be in the rearview mirror for the drugmaker.
Can Centene's Medicare Advantage Strategy Unlock Better Margins?
CNC is set to reshape its Medicare Advantage business around dual-eligible members and a simpler footprint to drive margin recovery.
Can Centene's Medicare Advantage Strategy Unlock Better Margins?
CNC is set to reshape its Medicare Advantage business around dual-eligible members and a simpler footprint to drive margin recovery.
Can Centene's Medicare Advantage Strategy Unlock Better Margins?
CNC is set to reshape its Medicare Advantage business around dual-eligible members and a simpler footprint to drive margin recovery.
📰
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?
Altimmune (ALT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰
Why Is Altimmune (ALT) Up 14.2% Since Last Earnings Report?
Altimmune (ALT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
📰
Hassett Sees Fiscally Responsible Path to $5,000 Payment
White House National Economic Council Director Kevin Hassett says President Donald Trump’s suggestion of sending $5,000 checks to every adult US...
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s
LLY's immunology portfolio is gaining ground, with steady revenue growth, pipeline expansion and acquisitions broadening its next wave.
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s
LLY's immunology portfolio is gaining ground, with steady revenue growth, pipeline expansion and acquisitions broadening its next wave.
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s
LLY's immunology portfolio is gaining ground, with steady revenue growth, pipeline expansion and acquisitions broadening its next wave.
Eli Lilly's Immunology Push Builds New Growth Engines Beyond GLP-1s
LLY's immunology portfolio is gaining ground, with steady revenue growth, pipeline expansion and acquisitions broadening its next wave.
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery
RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery
RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery
RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.
Revvity to Acquire Human Cell Design to Boost Metabolic Discovery
RVTY's HCD deal is expected to add human pancreatic beta cell models, expanding drug discovery and preclinical research tools for metabolic diseases.
MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE
Merck is expanding its pipeline and newer drug portfolio to offset Keytruda's 2028 LOE and drive long-term growth.
MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE
Merck is expanding its pipeline and newer drug portfolio to offset Keytruda's 2028 LOE and drive long-term growth.
MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE
Merck is expanding its pipeline and newer drug portfolio to offset Keytruda's 2028 LOE and drive long-term growth.
MRK Banks on Growing Pipeline & New Drugs to Offset Keytruda LOE
Merck is expanding its pipeline and newer drug portfolio to offset Keytruda's 2028 LOE and drive long-term growth.
3 Top Dividend Aristocrats To Own Near All-Time Highs
Several Dividend Aristocrats, including Johnson & Johnson (JNJ), Coca-Cola (KO), and Exxon Mobil (XOM), are trading near all-time highs, reflecting...